That is right Guzz. IMO, Jon is a very good CEO and Neuren is a great business. Both business and science wise, all the boxes are being ticked.
All we need now is for the remainder of the 2591 P2 trials to deliver what is widely (and reasonably) expected and we will all be holders of a transformative Australian biotech company, which will assist in improving the lives of many, many sufferers of some rare but debilitating neurological conditions.
A great journey so far.
NEU Price at posting:
$20.38 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)